Ipsen's Reloxin faces US delay
This article was originally published in Scrip
Executive Summary
The US FDA has extended the user fee date for the BLA for Ipsen's neuromuscular blocker Reloxin (botulinum toxin of type A) for the treatment of glabellar (frown) lines, an aesthetic indication, to April 13th.